Merck & Co might be able to find another use for its immunotherapy Keytruda in first line head and neck cancer, after revealing promising phase 3 trial results.
Novartis has announced it would not raise drug prices in the US this year, while Merck & Co announced huge cuts in the price of its hepatitis drug following pressure from president Trum
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh